Evogene Ltd.
EVGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 50.9% | 236.7% | 80.1% | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 39.8% | 24.8% | -105.9% | -222.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -180.7% | -411.4% | -1,607.9% | -2,988.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -193.7% | -423.4% | -1,590.3% | -2,988.5% |
| EPS Diluted | -2.89 | -5.23 | -6.46 | -0.68 |
| % Growth | 44.7% | 19% | -850% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |